Please assess the completion status of the following clinical trial:

Trial Title: On Open-Label Study in Participants With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed 52 weeks of treatment in core studies (NCT01196091) (NCT01205438)~* Given written informed consent~* Test negative for pregnancy at the time of enrollment~* Agree to use a reliable method of birth control~Exclusion Criteria:~* Unwilling to comply with study procedures~* Any condition that renders the participants unable to understand the nature and scope and possible consequences of the study~* Any condition that in the opinion of the investigator poses an unacceptable risk to the participants if study drug would be administered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY 2127399 Q2W (Type: EXPERIMENTAL): If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
- LY2127399 Q4W (Type: EXPERIMENTAL): If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).